• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Stephen Marmaras: Patient-Friendly Biosimilars Resources


Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses credible, patient-friendly resources that people with rheumatic diseases can access when they or their providers are considering a switch to a biosimilar.


What are some credible, patient-friendly resources that people with rheumatic diseases should access when they or their providers are considering a switch to a biosimilar?

I think the good news is that there’s a lot of resources out there right now. I would start with the FDA, they recently put out some new resources—some new educational content with everything right down to some sample social media content which is I think a great step for FDA to be moving into social media. That was encouraging to see.

I would also encourage some of our resources at a site we have, called 50statenetwork.org, where we have some kind of bullet-point-level information about biosimilars. We try and keep it very concise and approachable for advocates in our community.

But we do not have a monopoly on this information at all. [We] absolutely encourage folks to look up other arthritis organizations that they trust and know out there. [We] would also encourage checking out some major medical institutions like the Mayo Clinic or Cleveland Clinic.

And then also looking at the biosimilar manufacturers themselves. There’s [merckclarifiesbiosimilars.com], there’s pfizerbiosimilars.com as well. I think, like anything else out there, it’s important to look at really a diverse range of resources and use that to kind of bring your understanding of the content to another level.

I think what is encouraging is that there are coalitions out there that have begun to form that are kind of collections of a lot of these stakeholders and taking on education as a number one priority. So that’s something that has missed is educational content from 1 source that is a collection of stakeholders. I would recommend the Biosimilars Forum; [it] will hopefully be producing some content soon. That could be a source for some very diverse range of opinion in 1 spot.

Related Videos
Lakesha Farmer, PharmD
Lakesha Farmer from Cencora
Jeffrey Casberg, RPh, MS.
Adam Colborn, JD.
Legal scale weighs profit as greater than medical treatment
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Related Content
© 2024 MJH Life Sciences

All rights reserved.